Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Quest Diagnostics Inc (DGX) vs iShares China Large-Cap ETF (FXI) Price & Performance

Quest Diagnostics IncTrade
iShares China Large-Cap ETFTrade

Price performance (Past 24H)

Key statistics

Quest Diagnostics Inc vs iShares China Large-Cap ETF — how do they compare? Quest Diagnostics Inc trades at $237.51 (market cap $26.21B), while iShares China Large-Cap ETF trades at $35.22. The key difference: Quest Diagnostics Inc pays a 1.45% dividend while iShares China Large-Cap ETF pays none, and Quest Diagnostics Inc is trading nearer its 52-week high, iShares China Large-Cap ETF nearer its low. Which is the better fit depends on your goals.

DGXFXI
Market Cap
$26.21B
Sector
Health
52-Week High
$238.50$41.75
52-Week Low
$173.49$31.59
Enterprise Value
$31.97B
Dividend Yield
1.45%

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Quest Diagnostics Inc

Quest Diagnostics (DGX) trades at $237.99, up 0.15% on the day, near its 52-week high. The stock shows strong momentum with consecutive earnings beats in 2026, including Q2 EPS of $3.12 versus $2.82 expected. Revenue growth accelerated to $11.04 billion in 2025, with net income margin at 9.19%. Technical indicators signal a bullish trend, while analyst consensus is a $249.50 price target. Recent news highlights AI integration and raised 2026 outlook amid robust testing demand.

The outlook for DGX is positive, driven by earnings momentum, strategic partnerships, and healthcare demand. Investment opportunity lies in sustained growth and dividend yield, but risks include margin pressure from lower-margin deals and high debt levels. Valuation at a P/E of 25.21 requires continued execution to justify upside.

iShares China Large-Cap ETF

FXI trades at $35.23, down 3.45% on the day amid broader Chinese stock pressure. Technical indicators show a bullish overall signal with moving averages supporting upside momentum, while oscillators remain neutral. The ETF benefits from China's export strength and AI-driven manufacturing rebound, though financial ratios are currently unavailable. Recent news highlights China's 23% July export growth and ongoing infrastructure investments to support economic stability.

FXI offers exposure to China's large-cap recovery with state-backed stimulus and AI export growth as key catalysts. However, geopolitical tensions and US-China tech restrictions pose significant risks. The ETF's heavy financial sector weighting provides stability but limits pure tech exposure, requiring careful monitoring of China's economic policies and global trade dynamics.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Quest Diagnostics Inc

Quest Diagnostics is a leading independent provider of diagnostic testing, information, and services in the U.S. The company generates over 95% of its revenue through clinical testing, anatomic pathology, esoteric testing, and substance abuse testing with specimens collected at its national network of roughly 2,300 patient service centers, as well as multiple doctors offices and hospitals. The firm also runs a much smaller diagnostic solutions segment that provides clinical trials testing, risk assessment services, and information technology solutions.

Read more on DGX

About iShares China Large-Cap ETF

The fund generally will invest at least 80% of its assets in the component securities of its underlying index and in investments that have economic characteristics that are substantially identical to the component securities of its underlying index. The index designed to measure the performance of the largest companies in the Chinese equity market that trade on the Stock Exchange of Hong Kong and are available to international investors. The fund is non-diversified.

Read more on FXI